Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women - PubMed (original) (raw)
Comparative Study
Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women
Early Breast Cancer Trialists' Collaborative Group. N Engl J Med. 1988.
Abstract
We sought information worldwide on mortality according to assigned treatment in all randomized trials that began before 1985 of adjuvant tamoxifen or cytotoxic therapy for early breast cancer (with or without regional lymph-node involvement). Coverage was reasonably complete for most countries. In 28 trials of tamoxifen nearly 4000 of 16,513 women had died, and in 40 chemotherapy trials slightly more than 4000 of 13,442 women had died. The 8106 deaths were approximately evenly distributed over years 1, 2, 3, 4, and 5+ of follow-up, with little useful information beyond year 5. Systematic overviews of the results of these trials demonstrated reductions in mortality due to treatment that were significant when tamoxifen was compared with no tamoxifen (P less than 0.0001), any chemotherapy with no chemotherapy (P = 0.003), and polychemotherapy with single-agent chemotherapy (P = 0.001). In tamoxifen trials, there was a clear reduction in mortality only among women 50 or older, for whom assignment to tamoxifen reduced the annual odds of death during the first five years by about one fifth. In chemotherapy trials there was a clear reduction only among women under 50, for whom assignment to polychemotherapy reduced the annual odds of death during the first five years by about one quarter. Direct comparisons showed that combination chemotherapy was significantly more effective than single-agent therapy, but suggested that administration of chemotherapy for 8 to 24 months may offer no survival advantage over administration of the same chemotherapy for 4 to 6 months. Because it involved several thousand women, this overview was able to demonstrate particularly clearly that both tamoxifen and cytotoxic therapy can reduce five-year mortality.
Comment in
- Therapy for early breast cancer.
Heath RC. Heath RC. N Engl J Med. 1989 Jun 8;320(23):1558. doi: 10.1056/NEJM198906083202314. N Engl J Med. 1989. PMID: 2725589 No abstract available.
Similar articles
- Multi-agent chemotherapy for early breast cancer.
Early Breast Cancer Trialists' Collaborative Group. Early Breast Cancer Trialists' Collaborative Group. Cochrane Database Syst Rev. 2002;(1):CD000487. doi: 10.1002/14651858.CD000487. Cochrane Database Syst Rev. 2002. PMID: 11869577 Updated. Review. - Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis.
Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A. Cole BF, et al. Lancet. 2001 Jul 28;358(9278):277-86. doi: 10.1016/S0140-6736(01)05483-6. Lancet. 2001. PMID: 11498214 Review.
Cited by
- Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer.
Chadha M, White J, Swain SM, Rakovitch E, Jagsi R, Whelan T, Sparano JA. Chadha M, et al. NPJ Breast Cancer. 2023 Dec 14;9(1):99. doi: 10.1038/s41523-023-00591-6. NPJ Breast Cancer. 2023. PMID: 38097623 Free PMC article. Review. - "Moderate" adjuvant chemotherapy-induced leukopenia is beneficial for survival of patients with early breast cancer: a retrospective study.
Wang L, Jiang C, Wang N, Wen YL, Wang SF, Xue C, Bi XW, Yuan ZY. Wang L, et al. BMC Cancer. 2023 Dec 13;23(1):1227. doi: 10.1186/s12885-023-11680-x. BMC Cancer. 2023. PMID: 38093246 Free PMC article. - Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy.
Thomas NS, Scalzo RL, Wellberg EA. Thomas NS, et al. Nat Rev Endocrinol. 2024 Jan;20(1):16-26. doi: 10.1038/s41574-023-00899-0. Epub 2023 Oct 2. Nat Rev Endocrinol. 2024. PMID: 37783846 Review. - Treatment Outcomes according to the EndoPredict Score in ER-Positive, HER2-Negative Early Breast Cancer.
Jung W, Kim K, Moon BI. Jung W, et al. Breast Care (Basel). 2022 Dec;17(6):561-566. doi: 10.1159/000525838. Epub 2022 Jul 6. Breast Care (Basel). 2022. PMID: 36590151 Free PMC article. - An update on the pathological classification of breast cancer.
Rakha EA, Tse GM, Quinn CM. Rakha EA, et al. Histopathology. 2023 Jan;82(1):5-16. doi: 10.1111/his.14786. Histopathology. 2023. PMID: 36482272 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical